Background And Summary: Extracorporeal photopheresis (ECP) is a leukapheresis-based procedure used in the therapy of acute and chronic graft-versus-host disease (aGvHD, cGvHD) and other diseases. Based on the substantial efficacy and the excellent safety profile in the absence of immunosuppression ECP has established itself as a major treatment form for steroid-refractory GvHD. Here we review the current literature on ECP as a treatment option for patients with aGvHD as well as cGvHD.
Key Messages: ECP is a well-established second-line therapy for cGvHD. Its role in the treatment of aGvHD is less clear but also points towards an effective second-line therapy option. In the future ECP could play a role in the prevention of GvHD. More experimental and randomized controlled trials are needed to define the best patient selection criteria, settings, and therapy regimens for GvHD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315199 | PMC |
http://dx.doi.org/10.1159/000508169 | DOI Listing |
Arch Dermatol Res
January 2025
Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Transplant Proc
January 2025
Nefrology Department, Universitary Hospital Virgen de la Arrixaca, Murcia, Spain.
T-cell mediated rejection (TCMR) in renal transplantation, although reduced by better immunosuppressants, still impacts graft survival. TCMR responds to methylprednisolone (MPL) in 60% to 70% of cases, with polyclonal anti-T-lymphocyte antibodies (ATGs) used for severe or corticoresistant cases. When ATG is contraindicated, extracorporeal photopheresis (ECP) may be an alternative.
View Article and Find Full Text PDFTransfusion
January 2025
Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain.
Background: Extracorporeal photopheresis (ECP) product characteristics are not well established. The aim of this study was to compare mononuclear cells (MNCs) collection using the new Amicus blue (AB) In-line ECP system to our standard Off-line ECP system using the Optia apheresis device and the MacoGenic G2 inactivation system (OM).
Study Design And Methods: We assessed the ECP products and procedure parameters, patient characteristics, and adverse events for both AB and OM systems in paired patients.
There are no good evidence-based recommendations for any systemic treatment of erosive lichen planus (ELP). Extracorporeal photopheresis (ECP) may be an effective therapy for recalcitrant forms of the disease. We report 3 patients with severe ELP treated with ECP.
View Article and Find Full Text PDFFront Immunol
December 2024
Department of Neurology, Specialized Rehabilitation Hospital/Capital Health, Abu Dhabi, United Arab Emirates.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!